BRIEF published on 09/17/2025 at 14:05, 8 months 29 days ago Medincell and Teva Present Phase 3 Olanzapine LAI Data Phase 3 Trial Schizophrenia Treatment Medincell Teva Olanzapine LAI
PRESS RELEASE published on 09/17/2025 at 14:00, 8 months 29 days ago Inside Information / Other news releases Medincell and Teva to discuss Phase 3 Olanzapine LAI data from SOLARIS Trial at 2025 Psych Congress. Webcast details available on Teva's IR website Phase 3 Medincell Teva SOLARIS Trial Olanzapine LAI
BRIEF published on 09/12/2025 at 07:35, 9 months 4 days ago Medincell Appoints Three New Board Members Innovation Biopharmaceutical Leadership Board Appointments Medincell
PRESS RELEASE published on 09/12/2025 at 07:30, 9 months 4 days ago Inside Information / Other news releases Medincell appoints Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to its Board of Directors, adding valuable expertise in biotech and pharmaceutical sectors Board Of Directors Medincell Dr. Sharon Mates Dr. Charles Kunsch Dr. Pascal Touchon
BRIEF published on 09/10/2025 at 21:46, 9 months 6 days ago UZEDY® Obtains Approval in South Korea Following Success in the United States Schizophrenia UZEDY Teva Handok Medical Supply Korean Market
PRESS RELEASE published on 09/10/2025 at 21:41, 9 months 6 days ago Inside Information / Other news releases Teva Handok announces regulatory approval for UZEDY® in South Korea by Ministry of Food and Drug Safety, following successful US launch. Medincell's long-acting injectable for schizophrenia shows strong commercial performance Regulatory Approval Schizophrenia Medincell Commercial Performance Teva Handok
BRIEF published on 08/04/2025 at 14:05, 10 months 12 days ago Medincell Announces its 2025 General Meeting Governance General Meeting Resolutions Remuneration Medincell
BRIEF published on 07/30/2025 at 14:34, 10 months 17 days ago Medincell's Rising Revenue and Upcoming Submissions Schizophrenia Treatment Teva Partnership Medincell Revenue UZEDY Sales Olanzapine Submission
PRESS RELEASE published on 07/30/2025 at 14:29, 10 months 17 days ago INSIDE INFORMATION / OTHER NEWS RELEASES Medincell's partner Teva Pharmaceuticals raises 2025 revenue outlook for UZEDY® to $190–$200M and confirms Olanzapine LAI on track for submission in 2025 Revenue Outlook Medincell Teva Pharmaceuticals Olanzapine LAI Submission
BRIEF published on 07/30/2025 at 13:47, 10 months 17 days ago Medincell's UZEDY® and Olanzapine LAI Forecast Promising Financial Outcomes Schizophrenia Treatment Teva Pharmaceuticals Medincell Revenue Forecast UZEDY® Performance Olanzapine LAI Development
Published on 06/17/2026 at 00:35, 5 hours 5 minutes ago INEO Tech Corp. Announces Closing of Private Placement and Debt Settlement
Published on 06/17/2026 at 00:28, 5 hours 12 minutes ago Apex Critical Metals Announces Filing of Technical Report on the Rift Rare Earth Project
Published on 06/17/2026 at 00:10, 5 hours 30 minutes ago Panther Minerals Announces Brokered Private Placement of up to $3,000,000
Published on 06/17/2026 at 00:00, 5 hours 40 minutes ago Onco-Innovations Completes Project with Kuano, Using Their Quantum-Based Platform to Deliver Insights for PNKP Inhibitor Technology Optimization
Published on 06/16/2026 at 23:10, 6 hours 30 minutes ago Crestone Air Partners, an Air T Business, Completes Acquisition of Arena Aviation Capital, Surpassing $3.6 Billion in Assets Under Management
Published on 06/17/2026 at 05:35, 4 minutes ago How to Build a Plug-in Balcony Solar System with Your Existing Portable Power Station
Published on 06/17/2026 at 04:15, 1 hour 25 minutes ago Frost & Sullivan White Paper Names Phancy Rise vGPU a Tier 1 Leading Platform
Published on 06/16/2026 at 19:05, 10 hours 35 minutes ago AT&S announces the Reference Share Price and the Conversion Price of the new deeply subordinated perpetual convertible bond with an early redemption option for the Company
Published on 06/16/2026 at 19:00, 10 hours 39 minutes ago R. STAHL Shareholders approve nearly all agenda items at the Annual General Meeting – Executive Board confirms annual forecast
Published on 06/16/2026 at 11:44, 17 hours 55 minutes ago Guillemot Corporation S.A. | Weekly report share buyback from June 8 to June 12 2026
Published on 06/15/2026 at 23:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES THE TEMPORARY SUSPENSION OF THE TRADING OF ITS SHARES
Published on 06/15/2026 at 18:57, 1 day 10 hours ago Reporting on share buyback transactions carried out between June 8 and June 11, 2026
Published on 06/15/2026 at 18:32, 1 day 11 hours ago Edenred strengthens its electric charging offering with the acquisition of The Mobility House Solutions
Published on 06/15/2026 at 18:30, 1 day 11 hours ago Increase in the resources allocated to the liquidity contract with ODDO BHF
